Impact of the Major Candida glabrata Triazole Resistance Determinants on the Activity of the Novel Investigational Tetrazoles VT-1598 and VT-1161
暂无分享,去创建一个
E. Garvey | C. M. Yates | P. D. Rogers | R. Schotzinger | N. Wiederhold | A. Nishimoto | W. Hoekstra | S. Whaley | Qing Zhang | P. Rogers
[1] J. Bohlius,et al. Morbidity and mortality of candidaemia in Europe: an epidemiologic meta-analysis. , 2019, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[2] S. Kelly,et al. In Vitro Activities of the Novel Investigational Tetrazoles VT-1161 and VT-1598 Compared to the Triazole Antifungals against Azole-Resistant Strains and Clinical Isolates of Candida albicans , 2019, Antimicrobial Agents and Chemotherapy.
[3] J. Tyndall,et al. Azole Resistance Reduces Susceptibility to the Tetrazole Antifungal VT-1161 , 2018, Antimicrobial Agents and Chemotherapy.
[4] R. Lynfield,et al. Changes in Prevalence of Health Care–Associated Infections in U.S. Hospitals , 2018, The New England journal of medicine.
[5] Christina M. Henderson,et al. VT-1598 inhibits the in vitro growth of mucosal Candida strains and protects against fluconazole-susceptible and -resistant oral candidiasis in IL-17 signalling-deficient mice , 2018, The Journal of antimicrobial chemotherapy.
[6] P. D. Rogers,et al. Relative Contribution of the ABC Transporters Cdr1, Pdh1, and Snq2 to Azole Resistance in Candida glabrata , 2018, Antimicrobial Agents and Chemotherapy.
[7] E. Garvey,et al. The novel fungal CYP51 inhibitor VT-1598 is efficacious alone and in combination with liposomal amphotericin B in a murine model of cryptococcal meningitis , 2018, The Journal of antimicrobial chemotherapy.
[8] P. Nyirjesy,et al. A phase 2, randomized, double‐blind, placebo‐controlled, dose‐ranging study to evaluate the efficacy and safety of orally administered VT‐1161 in the treatment of recurrent vulvovaginal candidiasis , 2018, American journal of obstetrics and gynecology.
[9] E. Garvey,et al. The Novel Fungal Cyp51 Inhibitor VT-1598 Is Efficacious in Experimental Models of Central Nervous System Coccidioidomycosis Caused by Coccidioides posadasii and Coccidioides immitis , 2018, Antimicrobial Agents and Chemotherapy.
[10] E. Garvey,et al. Fungal-specific Cyp51 inhibitor VT-1598 demonstrates in vitro activity against Candida and Cryptococcus species, endemic fungi, including Coccidioides species, Aspergillus species and Rhizopus arrhizus , 2018, The Journal of antimicrobial chemotherapy.
[11] T. Calandra,et al. Changes in the epidemiological landscape of invasive candidiasis , 2018, The Journal of antimicrobial chemotherapy.
[12] E. Garvey,et al. Design and optimization of highly-selective, broad spectrum fungal CYP51 inhibitors. , 2017, Bioorganic & medicinal chemistry letters.
[13] Z. Wawrzak,et al. Crystal Structure of the New Investigational Drug Candidate VT-1598 in Complex with Aspergillus fumigatus Sterol 14α-Demethylase Provides Insights into Its Broad-Spectrum Antifungal Activity , 2017, Antimicrobial Agents and Chemotherapy.
[14] E. Berkow,et al. Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species , 2017, Frontiers in microbiology.
[15] P. D. Rogers,et al. Azole Resistance in Candida glabrata , 2016, Current Infectious Disease Reports.
[16] J. Sobel,et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[17] O. Cornely,et al. Candida glabrata – unique features and challenges in the clinical management of invasive infections , 2015, Mycoses.
[18] J. Sobel,et al. Efficacy of the Clinical Agent VT-1161 against Fluconazole-Sensitive and -Resistant Candida albicans in a Murine Model of Vaginal Candidiasis , 2015, Antimicrobial Agents and Chemotherapy.
[19] Ronald N. Jones,et al. Regional data analysis of Candida non‐albicans strains collected in United States medical sites over a 6‐year period, 2006–2011 , 2014, Mycoses.
[20] D. Kelly,et al. The Clinical Candidate VT-1161 Is a Highly Potent Inhibitor of Candida albicans CYP51 but Fails To Bind the Human Enzyme , 2014, Antimicrobial Agents and Chemotherapy.
[21] E. Garvey,et al. Design and optimization of highly-selective fungal CYP51 inhibitors. , 2014, Bioorganic & medicinal chemistry letters.
[22] S. G. Chadwick,et al. UPC2A Is Required for High-Level Azole Antifungal Resistance in Candida glabrata , 2014, Antimicrobial Agents and Chemotherapy.
[23] L. Harrison,et al. Species Identification and Antifungal Susceptibility Testing of Candida Bloodstream Isolates from Population-Based Surveillance Studies in Two U.S. Cities from 2008 to 2011 , 2012, Journal of Clinical Microbiology.
[24] D. Horn,et al. The PATH (Prospective Antifungal Therapy) Alliance® registry and invasive fungal infections: update 2012. , 2012, Diagnostic microbiology and infectious disease.
[25] M. Ghannoum,et al. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. , 2011, Diagnostic microbiology and infectious disease.
[26] Ramin Homayouni,et al. Genomewide Expression Profile Analysis of the Candida glabrata Pdr1 Regulon , 2010, Eukaryotic Cell.
[27] J. Sobel. Changing trends in the epidemiology of Candida blood stream infections: a matter for concern? , 2010, Critical care medicine.
[28] A. Rodloff,et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-Year Analysis of Susceptibilities of Candida Species to Fluconazole and Voriconazole as Determined by CLSI Standardized Disk Diffusion , 2010, Journal of Clinical Microbiology.
[29] G. Fadda,et al. The ATP‐binding cassette transporter–encoding gene CgSNQ2 is contributing to the CgPDR1‐dependent azole resistance of Candida glabrata , 2008, Molecular microbiology.
[30] Clinical,et al. Reference method for broth dilution antifungal susceptibility testing of yeasts : Approved standard , 2008 .
[31] R. Homayouni,et al. Pdr1 regulates multidrug resistance in Candida glabrata: gene disruption and genome‐wide expression studies , 2006, Molecular microbiology.
[32] J. Bennett,et al. Candida glabrata PDR1, a Transcriptional Regulator of a Pleiotropic Drug Resistance Network, Mediates Azole Resistance in Clinical Isolates and Petite Mutants , 2006, Antimicrobial Agents and Chemotherapy.
[33] M. Choti,et al. Triazole Cross-Resistance among Candida spp.: Case Report, Occurrence among Bloodstream Isolates, and Implications for Antifungal Therapy , 2006, Journal of Clinical Microbiology.
[34] B. Arthington-Skaggs,et al. Rapid Acquisition of Stable Azole Resistance by Candida glabrata Isolates Obtained before the Clinical Introduction of Fluconazole , 2005, Antimicrobial Agents and Chemotherapy.
[35] G. Fadda,et al. Mechanisms of Azole Resistance in Clinical Isolates of Candida glabrata Collected during a Hospital Survey of Antifungal Resistance , 2005, Antimicrobial Agents and Chemotherapy.
[36] R. Kolter,et al. The SAT1 flipper, an optimized tool for gene disruption in Candida albicans. , 2004, Gene.
[37] T. Edlind,et al. Azole Resistance in Candida glabrata: Coordinate Upregulation of Multidrug Transporters and Evidence for a Pdr1-Like Transcription Factor , 2004, Antimicrobial Agents and Chemotherapy.
[38] Shane Gillespie,et al. Attributable mortality of nosocomial candidemia, revisited. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[39] D. Sanglard,et al. Role of ATP-Binding-Cassette Transporter Genes in High-Frequency Acquisition of Resistance to Azole Antifungals in Candida glabrata , 2001, Antimicrobial Agents and Chemotherapy.
[40] D. Sanglard,et al. The ATP Binding Cassette Transporter GeneCgCDR1 from Candida glabrata Is Involved in the Resistance of Clinical Isolates to Azole Antifungal Agents , 1999, Antimicrobial Agents and Chemotherapy.
[41] D. Ward,et al. Fluconazole Resistance Associated with Drug Efflux and Increased Transcription of a Drug Transporter Gene, PDH1, inCandida glabrata , 1998, Antimicrobial Agents and Chemotherapy.